Research Article
Screening of Cognitive Impairment in Patients with Multiple Sclerosis: A Cross-Sectional Study in Georgia
Table 5
Characteristics of MS patients with and without DMT.
| | MS patients on DMT | MS patients without DMT |
| Number of subjects, n (%) | 27 (40%) | 41 (60%) | Age (years), mean ± SD | 37.6 ± 9.2 | 40.3 ± 10.4 | Female, n (%) | 18 (66.7%) | 30 (73%) | Male, n (%) | 9 (33.3%) | 11 (27%) | Education < 15 years | 19 (70%) | 20 (49%) | Education ≥15 years | 8 (30%) | 21 (51%) | Unemployed | 12 (44%) | 20 (49%) | Employed | 25 (55%) | 35 (59%) |
| MS subtype | RRMS | 23 (85%) | 29 (70.7%) | SPMS | 4 (15%) | 8 (19.5%) | PPMS | — | 4 (9.8%) |
| Disease duration (years), mean ± SD | 6.7 ± 4.6 | 7.1 ± 6.5 | EDSS (years), mean ± SD | 2.6 ± 1.3 | 3.7 ± 1.7 | BDI ≥ 19 | 3 (11%) | 11 (27%) | CI | 11 (41%) | 21 (51%) |
|
|
BDI: Beck Depression Inventory; CI: cognitive impairment; DMT: disease-modifying therapy; EDSS: Expanded Disability Status Scale; PPMS: primary progressive multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; SD: standard deviation; SPMS: secondary progressive multiple sclerosis.
|